<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of this prospective study was to determine whether <z:chebi fb="0" ids="2636">amifostine</z:chebi> (<z:chebi fb="0" ids="2636">Ethyol</z:chebi>) reduced conditioning-related toxicity following a regimen of <z:chebi fb="0" ids="28901">busulfan</z:chebi> (7 mg/kg) and fractionated total body irradiation (6 x 200 cGy) </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 12 patients with advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> transplanted from HLA-identical siblings were enrolled </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received 340 mg/m(2) <z:chebi fb="0" ids="2636">amifostine</z:chebi> i.v. twice daily during conditioning (days -7 through -1) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients developed <z:e sem="disease" ids="C1290331" disease_type="Disease or Syndrome" abbrv="">oropharyngeal mucositis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Six patients had evidence of <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">sinusoidal obstruction syndrome</z:e> of the liver </plain></SENT>
<SENT sid="5" pm="."><plain>Six patients experienced pulmonary toxicity of grades II-III </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 11 patients died, one with relapse and 10 with infectious complications or regimen-related toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>Nonrelapse causes of <z:hpo ids='HP_0011420'>death</z:hpo> included invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> in three, multiorgan failure in three, and idiopathic <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> in two patients </plain></SENT>
<SENT sid="8" pm="."><plain>One patient each died of organizing <z:hpo ids='HP_0002090'>pneumonia</z:hpo> and CMV <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>One patient is alive in complete remission 31 months after transplantation </plain></SENT>
<SENT sid="10" pm="."><plain>These results were not superior to those in patients conditioned with <z:chebi fb="0" ids="28901">busulfan</z:chebi> plus fractionated total body irradiation and not given <z:chebi fb="0" ids="2636">amifostine</z:chebi>, and suggest that <z:chebi fb="0" ids="2636">amifostine</z:chebi>, as administered here, has no protective effect against toxicity from this myeloablative regimen </plain></SENT>
</text></document>